EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Two-year treatment outcomes after anti-vascular endothelial growth factor therapy in age-related macular degeneration with type 2 macular neovascularization in Japanese patients

Yosuke Fukuda, Satomi Shiose, Shoji Notomi, Yusuke Maehara, Kenichiro Mori, Sawako Hashimoto, Kumiko Kano, Keijiro Ishikawa, Koh-Hei Sonoda

Japanese Journal of Ophthalmology · 2025

DOI: 10.1007/s10384-025-01178-3 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Japanese Journal of Ophthalmology, 2025. Verfasst von Yosuke Fukuda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Bevacizumab, Macula Lutea, Ranibizumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Neovascular age-related macular degeneration (nAMD) with type 2 macular neovascularization (MNV) has a relatively good responsiveness to anti-vascular endothelial growth factor (anti-VEGF) therapy compared to type 1 MNV. This study aimed to analyze the treatment outcomes of nAMD patients with type 2 MNV and identify factors associated with fluid recurrence. STUDY DESIGN: Retrospective observational study. METHODS: This study included treatment-naïve nAMD patients with type 2 MNV but without type 1 MNV, who received 3-monthly anti-VEGF injections as the loading phase and were followed up for over 2 years. The treatment outcomes were compared between proactive (PA) and reactive regimen (RA) groups. In addition, we investigated the factors associated with fluid recurrence in the RA group. RESULTS: This retrospective study included 65 eyes from 65 patients. Best-corrected visual acuity (BCVA) and central macular thickness significantly improved in both the PA and RA groups. Although there was no significant difference between the two groups, the RA group showed a trend towards better BCVA. The presence of fluid three or four months after the initial injection was associated with fluid recurrence in the RA group (p = 0.02). CONCLUSION: For nAMD patients with type 2 MNV, a proactive regimen is generally preferred. However, for nAMD patients with type 2 MNV achieving fluid resolution after the loading phase, it may be possible to maintain BCVA and reduce the number of anti-VEGF injections by following a reactive regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsBevacizumabMacula LuteaRanibizumabVisual AcuityWet Macular DegenerationAgedAged, 80 and overFemaleHumansMaleMiddle AgedFluorescein AngiographyFollow-Up StudiesFundus OculiIntravitreal InjectionsJapanRetrospective StudiesTime FactorsTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor A

Stichwörter der Autor:innen

Anti-vascular endothelial growth factor therapyNeovascular age-related macular degenerationPro re nataTreat and extendType 2 macular neovascularization

Substanzen

Angiogenesis InhibitorsBevacizumabRanibizumabVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
  • Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. asshyharyu@gmail.com.

Förderung

  • Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research

Zitieren

APA

Fukuda, Y., Shiose, S., Notomi, S., Maehara, Y., Mori, K., Hashimoto, S., Kano, K., Ishikawa, K., & Sonoda, K. H. (2025). Two-year treatment outcomes after anti-vascular endothelial growth factor therapy in age-related macular degeneration with type 2 macular neovascularization in Japanese patients. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-025-01178-3

Vancouver

Fukuda Y, Shiose S, Notomi S, Maehara Y, Mori K, Hashimoto S, et al. Two-year treatment outcomes after anti-vascular endothelial growth factor therapy in age-related macular degeneration with type 2 macular neovascularization in Japanese patients. Japanese Journal of Ophthalmology. 2025. doi:10.1007/s10384-025-01178-3

BibTeX
@article{Fukuda2025,
  author = {Fukuda, Yosuke and Shiose, Satomi and Notomi, Shoji and Maehara, Yusuke and Mori, Kenichiro and Hashimoto, Sawako and Kano, Kumiko and Ishikawa, Keijiro and Sonoda, Koh-Hei},
  title = {Two-year treatment outcomes after anti-vascular endothelial growth factor therapy in age-related macular degeneration with type 2 macular neovascularization in Japanese patients},
  journal = {Japanese Journal of Ophthalmology},
  year = {2025},
  doi = {10.1007/s10384-025-01178-3}
}
Kostenlos starten →